Completed Lungs & Breathing Brain & Nervous System

Role of ATP in Chronic Cough

In plain English

AI plain-English summary

A drug that blocks the release of ATP is already known to stop chronic coughing in some patients, but no one understands why it works or whether it will help people with other lung diseases. This matters because chronic cough—a cough that persists for months or years without a clear cause—affects millions of people, and current treatments often fail. The research addresses a critical gap: while ATP has been identified as a driver of treatment-resistant chronic cough, the mechanisms behind its release and its role across different respiratory conditions remain unknown. The team has also found that patients with different lung diseases have distinct nerve-based cough profiles, suggesting that a single drug may not work for everyone. If successful, this project could identify new drug targets upstream of ATP release, develop biomarkers to predict which patients will respond to treatment, and clarify how the upper airway contributes to cough sensations. The practical outcome would be more precise, personalised treatments for chronic cough—moving beyond a one-size-fits-all approach to therapies tailored to specific underlying disease mechanisms.

View original technical description
The cough reflex is triggered by ion channels present on vagal nerve termini which can be activated by a wide variety of irritants. Utilising a P2X3 antagonist we have identified ATP as a driver of chronic idiopathic cough which is treatment refractory. However, the mechanisms are not known and it is not clear whether similar efficacy will be observed in chronic cough associated with common respiratory diseases. We have identified different neurophenotypes in patients with chronic cough associated with different lung diseases suggesting that a single therapeutic may not address cough across all indications and that mechanistic information will be required. Furthermore, upstream targets, involved in the release of ATP, may provide a broader efficacy profile as ATP has been shown to have a range of disease relevant biological effects in the lung mediated by purinoceptors. We will identify (1) whether ATP is a biomarker of treament sensitivity; (2) upstream targets involved in the release of ATP; (3) the contribution of the upper airway to ATP-induced sensations; (4) the role of ATP in mediating chronic cough across other airway diseases? This project will identify novel targets, biomarkers and the patient phenotypes that will respond to treatment.

View the original record at the funder ↗

Researchers

Jacky Smith (EPMC Awardee)Maria Belvisi (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Neuroinflammatory interactions of ATP and P2X3 receptor in the airways of chronic cough patients: an exploratory study
Neuroinflammatory interactions of adenosine triphosphate (ATP) and P2X3 receptor in the airways of chronic cough patients: an exploratory study
Adenosine Triphosphate (ATP) in the Airways and Plasma in Chronic Cough
ANTHEM: Are ATP levels in the blood and airways higher in people with chronic cough?
Are ATP levels in the blood and airways higher in people with chronic cough?

Original classification

Investigator Award in Science

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.